J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0091270009336233v1
49/6/668    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Google Scholar
Right arrow Articles by Lee, C. Y. W.
Right arrow Articles by Burnett, J. C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, C. Y. W.
Right arrow Articles by Burnett, J. C., Jr.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

PHARMACODYNAMICS

Pharmacodynamics of a Novel Designer Natriuretic Peptide, CD-NP, in a First-in-Human Clinical Trial in Healthy Subjects

Candace Y. W. Lee, MD, PhD, FCP, Horng H. Chen, MB, BCh, Ondrej Lisy, MD, PhD, Suzanne Swan, MD, Courtney Cannon, Hsiao D. Lieu, MD and John C. Burnett, Jr., MD

From the Cardiorenal Research Laboratory, Division of Cardiovascular Diseases and Departments of Medicine and Physiology (Dr Lee, Dr Chen, Dr Lisy, Dr Burnett), and Division of Clinical Pharmacology, Department of Molecular Pharmacology & Experimental Therapeutics (Dr Lee, Dr Burnett), Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minnesota; DiVita Clinical Research, Hennepin County Medical Center, University of Minnesota, Minneapolis, Minnesota (Dr Swan, Ms Cannon); and Nile Therapeutics, Inc, San Francisco, California (Dr Lieu).

CD-NP is a novel chimeric natriuretic peptide (NP) consisting of the 22-amino-acid (AA) human C-type natriuretic peptide (CNP), a venodilating peptide with limited renal actions and minimal effects on blood pressure, and the 15-AA C-terminus of Dendroaspis NP (DNP). The rationale for the design of CD-NP was to enhance the renal actions of CNP, the ligand for natriuretic peptide receptor-B, but without inducing excessive hypotension. Here we report the first-in-human studies for CD-NP, which represent the first successful clinical testing of a chimeric NP demonstrating in normal human volunteers that CD-NP possesses cyclic guanosine monophosphate-activating, natriuretic, and aldosterone-suppressing properties without inducing excessive hypotension, laying the foundation for additional studies on this first-in-class new cardiovascular therapeutic in human heart failure, which are now underway worldwide.

Key Words: Chimeric natriuretic peptide • CD-NP • C-type natriuretic peptide • Dendroaspis natriuretic peptide

Address for reprints: John C. Burnett, Jr, MD, Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905;e-mail: burnett.john{at}mayo.edu.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American College of Clinical Pharmacology